Compositions and methods of manufacturing trivalent filovirus vaccines
AssigneesSoligenix, Inc., University of Hawaii
InventorsOreola Donini, Axel Lehrer
Life of this patent
Estimating the term…
Abstract
Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use. Also disclosed is a vaccine composition comprising at least two antigens, wherein each antigen is specific to a different genus of filovirus and which also comprises at least one nano-emulsion adjuvant.
Claims8
A stable, immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen, wherein the at least one antigen comprises a viral glycoprotein, and at least one adjuvant, wherein the at least one adjuvant comprises sucrose fatty acid sulphate esters and wherein the at least one antigen and the at least one adjuvant are co-lyophilized and reconstituted immediately prior to use.
A stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least two antigens, wherein each antigen is a viral glycoprotein specific to a different genus of filovirus and at least one nano-emulsion adjuvant.
A method of manufacturing a stable immunogenic composition capable of eliciting a robust and durable immune response to more than one virus, comprising at least two antigens, wherein each antigen is specific to a different virus from the same or different families and providing at least one adjuvant, wherein the at least one adjuvant comprises sucrose fatty acid sulphate esters and wherein the at least one antigen and the at least one adjuvant are co-lyophilized and reconstituted immediately prior to use, and further wherein the at least one adjuvant does not contain alum.
Dependencies are inferred from the claim text.